

Form PTO-1449 U.S. Department of Commerce

(REV. 8-83) Patent and Trademark Office

Atty. Docket No.
ENZ-53(D5)

Serial No. 08/978,637

INFORMATION DISCLOSURE CITATION

(use several sheets if necessary)

Applicants: Rabbani et al

Filed: November 15, 1997

Filed: November 15, 1997

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN- LATION YES NO
/AB/	WO 9 5 1 9 4 2 8	7/20/95				
/AB/	EP 0 5 4 7 9 2 0	6/23/93				
/AB/	WO 9 4 2 0 0 7 9	9/15/94				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/AB/	Chang, H-K, et al, "Block of HIV-1 infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1," <u>Gene Therapy</u> , Vol 1(3):208-216 (1994)
/AB/	Cohli, H., et al, "Inhibition of HIV-1 multiplication in a human CD4 lymphocytic cell line expressing antisense and sense RNA molecules containing HIV-1 packaging signal and rev response element(s)," <u>Antisense Research and Development</u> , Vol. 4:19-26 (1994)
/AB/	Tani, T., et al, "Activity of chimeric RNAs of U6 snRNA and (-)sTRSV in the cleavage of a substrate RNA," <u>Nucleic Acids Research</u> , Vol. 20(12):2991-2996 (1992)
/AB/	Michael, W.M., et al, "Signal sequences that target nuclear import and nuclear export of pre-mRNA-binding proteins," <u>Cold Spring Harbor Symposia on Quantitative Biology</u> , Vol. 60:663-668 (1995)
/AB/	McBride, K.E., et al, "Controlled expression of plastid transgenes in plants based on a nuclear DNA-encoded and plastid-targeted T7 RNA polymerase," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 91:7301-7305 (1994)

EXAMINER


/Amy Bowman/

DATE CONSIDERED

03/28/2007

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 U.S. Department of Commerce (REV. 8-83) Patent and Trademark Office INFORMATION DISCLOSURE CITATION (use several sheets if necessary)	Atty. Docket No. ENZ-53(D5)	Serial No. 08/978,637
	Applicants: Rabbani et al	
	Filed: November 15, 1997	Group: 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPRO- PRIATE

FOREIGN PATENT DOCUMENTS


	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN- SLATION YES NO
/AB/	W 9 5 2 8 4 9 4	10/26/95				
	O 9 5 3 2 2 2 5	11/30/95				
	W 9 5 3 1 5 6 6	11/23/95				
	O					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Afione, S.A., et al, "Gene therapy vectors as drug delivery system," <u>Clin. Pharmacokinet</u> , Vol. 28(3):181-189 (1995)
	Wagner, E., et al, "Coupling of adenovirus to transferring-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 89:6099-6103 (1992)
	Fuerst, T.R., et al, "Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 83:8122-8126 (1986)
	Chatterjee, S., et al, "Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector," <u>Science</u> , Vol. 258:1485-1488 (1992)
↓	Teem, J.L., et al, "Expression of a beta-galactosidase gene containing the ribosomal protein 51 intron is sensitive to the rna2 mutation of yeast," <u>Proc. Natl. Acad. Sci.</u> , Vol. 80(14): 4403-4407 (1983)

EXAMINER	/Amy Bowman/	DATE CONSIDERED	03/28/2007
----------	--------------	-----------------	------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	08/978,637
		Filing Date	Nov.25, 1997
		First Named Inventor	Rabbani
		Art Unit	1635
		Examiner Name	J. Schultz
Sheet 1	of 1	Attorney Docket Number	Enz53(D5)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/		Junker et al., 1995, Gene Therapy 2:639-645	
/AB/		Sullenberger et al., 1990, Mol. Cell. Biol. 10:6512-6523	

Examiner Signature	/Amy Bowman/	Date Considered	/Amy Bowman/
--------------------	--------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.